StageZero to Issue Q1 2023 Financial Results After Market Closes May 15, 2023
StageZero to Issue Q1 2023 Financial Results After Market Closes May 15, 2023
Toronto, Ontario--(Newsfile Corp. - May 15, 2023) - StageZero Life Sciences (TSX: SZLS) ("StageZero" or the "Company") today announced that it will release its first quarter 2023 operational results after the market closes on Monday May 15, 2023. StageZero's Chairman and CEO, James Howard-Tripp, will host an investor webcast and conference call at 8:30am ET on Tuesday May 16, 2023, reviewing the operational results and discussing business developments.
安大略省多倫多-(Newsfile Corp.-2023年5月15日)-StageZero生命科學公司(多倫多證券交易所股票代碼：SZLS)(以下簡稱“StageZero”或“公司”)今天宣佈，將在2023年5月15日星期一收盤後公佈2023年第一季度的運營業績。StageZero董事長兼首席執行官詹姆斯·霍華德-特裡普將於美國東部時間2023年5月16日星期二上午8：30主持投資者網路廣播和電話會議，回顧運營業績並討論業務發展。
Analyst and Investor Call
分析師和投資者電話會議
Event Date: Tuesday May 16, 2023
Time: 8:30 am ET
Webcast Link:
活動日期時間：2023年5月16日星期二
時間：美國東部時間上午8：30
網路直播鏈接：
Conference Call Numbers
電話會議號碼
Canada/USA TF: 1-800-319-4610
Toronto Toll: +1-416-915-3239
International Toll: +1-604-638-5340
加拿大/美國電話：1-800-319-4610
多倫多通行費：+1-416-915-3239
國際通行費：+1-604-638-5340
About StageZero Life Sciences, Ltd.
StageZero生命科學有限公司簡介
StageZero Life Sciences, Ltd. is a vertically integrated healthcare company dedicated to improving the early detection and management of cancer and other chronic diseases through next-generation diagnostics and a unique telehealth program that provides clinical interventions to help patients reduce the risk of developing late-stage disease (AVRT).
StageZero生命科學有限公司是一家垂直整合的醫療保健公司，致力於通過下一代診斷和獨特的遠端醫療計劃來改善癌症和其他慢性病的早期檢測和管理，該計劃提供臨床幹預措施，幫助患者降低發展為晚期疾病(AVRT)的風險。
The Company's next generation test, Aristotle, is the first ever mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. This underlying technology has been validated in more than 9,000 patients and used by more than 100,000 patients in North America.
該公司的下一代測試亞裡士多德是有史以來第一個同時從單一血液樣本中篩查多種癌症的信使核糖核酸多癌症小組，對每種癌症都具有高度的敏感性和特異性。亞裡士多德使用信使核糖核酸技術來識別多種癌症類型的分子特徵，並建立在該公司的專利技術平臺哨兵原理的基礎上。這項潛在的技術已經在9000多名患者中得到驗證，並在北美被10萬多名患者使用。
Aristotle, as well as additional cancer diagnostics (ColonSentry, BreastSentry, and the Prostate Health Index) are processed at the Company's clinical laboratory, StageZero Life Sciences, Inc., a CAP accredited and CLIA certified high-complexity reference laboratory in Richmond, Virginia. In addition, the Company is also leveraging its specialty in polymerase chain reaction (PCR) testing to provide COVID-19 PCR testing (swab and saliva) and Antibody Testing (blood analysis).
該公司的臨床實驗室StageZero生命科學公司是一家CAP認證和CLIA認證的高複雜性參考實驗室，位於弗吉尼亞州里士滿。此外，該公司還利用其在聚合酵素鏈式反應檢測方面的專長，提供新冠肺炎聚合酵素鏈式反應檢測(拭子和唾液)和抗體檢測(血液分析)。
StageZero Life Sciences trades on the Toronto Stock exchange under the symbol SZLS and on the OTCQB under the symbol SZLSF.
StageZero生命科學在多倫多證券交易所交易，代碼為SZLS，在OTCQB交易，代碼為SZLSF。
Forward-Looking Statements
前瞻性陳述
This press release contains forward-looking statements identified by words such as "expects", "will" and similar expressions, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties that could cause the Company's actual events to differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements, except as required by law.
本新聞稿包含以“期望”、“將”和類似表達方式標識的前瞻性陳述，它們反映了公司目前對未來事件的期望。前瞻性陳述涉及風險和不確定因素，這些風險和不確定因素可能導致公司的實際事件與本文所預測的大不相同。投資者應查閱公司正在提交的季度報告和年度報告，瞭解與這些前瞻性陳述有關的風險和不確定性的更多資訊。提醒讀者不要依賴這些前瞻性陳述。除法律要求外，公司不承擔任何更新這些前瞻性陳述的義務。
For further information please contact:
欲瞭解更多資訊，請聯繫：
Investor Relations
Rebecca Greco
1-855-420-7140 ext. 1838
rgreco@stagezerols.com
投資者關係
麗貝卡·格雷科
1-855-420-7140分機1838年
郵箱：rgreco@stagezerols.com
To view the source version of this press release, please visit
要查看本新聞稿的源版本，請訪問
譯文內容由第三人軟體翻譯。